Cytopeutics® is the multi-award winning and trusted provider of mesenchymal stem cells (MSC) for clinical trials and treatment in the Asia-Pacific region. With nearly two decades of evidence-based research and development, joint effort with scientists around the world, Cytopeutics® is also at the cutting edge of research exploring the potential of multicellular immunotherapy, including cytokine-induced killer cells (CIK) and polarized M2 macrophages.
To provide proven stem cell therapies in a professional, responsible and ethical manner for the benefit of people everywhere.
To be the global leader in stem cell treatment.
Cytopeutics® has concluded several clinical trial phase IIb/IIIa programs in partnerships with major universities and hospitals locally and internationally. These programs were approved by our ethics committees and national stem cell regulatory committee and registered with the US NIH registry.
The results of these studies have been presented at major scientific and clinical conferences such as the congress of the European Society of Cardiology (ESC) and the International Society for Cell Therapy (ISCT). Our abstracts and full papers have also been published in international peer-reviewed journals.
Send Us a Message
Cytopeutics® is the multi-award winning and trusted provider of mesenchymal stem cells (MSC) for clinical trials and treatment in the Asia-Pacific region.